4,8,12,17-Tetraazaicosane-1,20-diamine | 143085-73-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4,8,12,17-Tetraazaicosane-1,20-diamine
• 英文别名: N-(3-aminopropyl)-N'-[3-[3-(3-aminopropylamino)propylamino]propyl]butane-1,4-diamine
• CAS: 143085-73-8
• 化学式: C₁₆H₄₀N₆
• 分子量: 316.53
• InChiKey: RJHJECDDXKOIBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  22
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  100
• 氢给体数：
  6
• 氢受体数：
  6

文献信息

• Processes and host cells for genome, pathway, and biomolecular engineering
  申请人：enEvolv, Inc.

  公开号：US10370654B2

  公开（公告）日：2019-08-06

  The present disclosure provides compositions and methods for genomic engineering.

  本公开提供了基因组工程的组合物和方法。
• Lfa-1 inhibitors and use thereof
  申请人：Soda Kuniyasu

  公开号：US20060281820A1

  公开（公告）日：2006-12-14

  The present invention provides an LFA-1 inhibitor comprising at least one member selected from the group consisting of polyamines represented by general formula (1) and pharmaceutical acceptable salts thereof: NH 2 —(CH 2 )m1-(NH)p1-(CH 2 )m2-(NH)p2-(CH 2 )m3-(NH)p3-(CH 2 )m4-(NH)p4-(CH 2 )m5-NH 2 (1), wherein at least two of m1 to m5 exceed 0, each of m1 to m5 is independently an integer of 0 to 7, the sum of m1+m2+m3+m4+m5 is 2 or more but less than 18, at least one of p1, p2, p3 and p4 is 1, and each of others independently represents 0 or 1. The present invention also provides a pharmaceutical composition containing the LFA-1 inhibitor and a method for the inhibition or the treatment of diseases.
• LFA-1 Inhibitors and Use Thereof
  申请人：Soda Kuniyasu

  公开号：US20100004342A1

  公开（公告）日：2010-01-07

  The present invention provides an LFA-1 inhibitor comprising at least one member selected from the group consisting of polyamines represented by general formula (I) and pharmaceutical acceptable salts thereof: NH 2 —(CH 2 )m1-(NH)p1-(CH 2 )m2-(NH)p2-(CH 2 )m3-(NH)p3-(CH 2 )m4-(NH)p4-(Cl 2 )m5-NH 2 (1), wherein at least two of m1 to m5 exceed 0, each of m1 to m5 is independently an integer of 0 to 7, the sum of m1+m2+m3+m4+m5 is 2 or more but less than 18, at least one of p1, p2, p3 and p4 is 1, and each of others independently represents 0 or 1. The present invention also provides a pharmaceutical composition containing the LFA-1 inhibitor and a method for the inhibition or the treatment of diseases.
• PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING
  申请人：ENEVOLV, INC.

  公开号：US20160186168A1

  公开（公告）日：2016-06-30

  The present disclosure provides compositions and methods for genomic engineering.
• US9944925B2
  申请人：——

  公开号：US9944925B2

  公开（公告）日：2018-04-17